Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Glucosuric, renal and hemodynamic effects of a dual inhibitor of SGLT1 and SGLT2, licogliflozin, in patients with chronic kidney disease: a randomized trial.

< BACK TO ARCHIVE


2021 Jan 29


Diabetes Obes Metab


http://www.ncbi.nlm.nih.gov/pubmed/33512754?dopt=Abstract

Glucosuric, renal and hemodynamic effects of a dual inhibitor of SGLT1 and SGLT2, licogliflozin, in patients with chronic kidney disease: a randomized trial.

Authors

Glucosuric, renal and hemodynamic effects of a dual inhibitor of SGLT1 and SGLT2, licogliflozin, in patients with chronic kidney disease: a randomized trial.
He YL, Pachori A, Chen P, Ma S, Mendonza AE, Amer A, Marbury TC, Hinder M
Diabetes Obes Metab. 2021 Jan 29.
PMID: 33512754.

Abstract

The beneficial effects of SGLT2 inhibitors in patients with chronic kidney disease (CKD) have been demonstrated. Whether inhibition of both SGLT1 and SGLT2 confers additional benefits is unknown. This study investigated the glucosuric, renal and hemodynamic effects of a dual SGLT1/2 inhibitor, licogliflozin, in patients with CKD.
Read This Paper